Theranostic nanosystems are emerging as a promising approach for controlled drug delivery, diagnosis and multimodal therapeutics. Herein, a multifunctional theranostic nanoplatform is reported for photothermal-chemo combination therapy functioned with magnetic and thermal imaging. Hyaluronic acid (HA) coated Fe₃O₄@polydopamine nanoparticles equipped with redox-sensitive disulfide linkers have been subsequently deposited with an anticancer drug, doxorubicin (DOX) (termed as FPCH-DOX NPs). These nanocomposites possess an average diameter of 120 nm, a saturation magnetization of 28.5 emu g⁻¹, DOX loading capacity of 7.13% and a transverse relaxation rate of 171.76 mM⁻¹ s⁻¹. The drug release could be triggered by pH, glutathione (GSH) concentration and light irradiation. Prussian blue staining and confocal microscopy demonstrate that these nanoplatforms have improved biocompatibility and cellular uptake in CD44-positive HeLa cell lines rather than in CD44-negative NIH 3T3 normal cell lines. In vitro evaluations demonstrate that the combination therapy of FPCH-DOX NPs lowers the cell viability to 16.2%, less than that of individual chemotherapy (55.3%) or PTT (52.1%). In vivo MRI indicates that the tumor accumulation of FPCH-DOX NPs provides enhanced MRI contrast, and in vivo thermal imaging verified their localized photothermal conversion effect in tumor tissues. Importantly, FPCH-DOX NPs present remarkable anti-tumor efficacy by photothermal-chemo combination therapy. H&E and Ki67 staining tests show obvious necrosis and weak cell proliferation at the region of the tumor. Thus, FPCH-DOX NPs are promising multifunctional nanoplatforms for highly effective cancer theranostics.

中文翻译：

---

多功能治疗仪纳米系统，可通过磁共振成像对三刺激响应药物释放进行光热化学联合治疗。

治疗肿瘤的纳米系统正在成为一种有前途的方法，用于控制药物的输送，诊断和多模式治疗。在本文中，报道了一种多功能的治疗药物纳米平台，用于具有磁和热成像功能的光热化学联合疗法。配备有氧化还原敏感的二硫键的透明质酸（HA）涂层的Fe ₃ O ₄聚多巴胺纳米颗粒随后已沉积了抗癌药阿霉素（DOX）（称为FPCH-DOX NP）。这些纳米复合材料的平均直径为120 nm，饱和磁化强度为28.5 emu g ^-1，DOX负载量为7.13％，横向弛豫速率为171.76 mM ^-1 s ^-1。pH，谷胱甘肽（GSH）浓度和光照射均可触发药物释放。普鲁士蓝染色和共聚焦显微镜表明，这些纳米平台在CD44阳性HeLa细胞系中而不是在CD44阴性NIH 3T3正常细胞系中具有改善的生物相容性和细胞摄取。体外评估表明，FPCH-DOX NPs的联合治疗可将细胞活力降低至16.2％，低于单个化疗（55.3％）或PTT（52.1％）。体内MRI显示FPCH-DOX NPs的肿瘤积累提供了增强的MRI对比度，而在体内热成像证实了它们在肿瘤组织中的局部光热转化作用。重要的是，通过光热化学联合疗法，FPCH-DOX NPs具有显着的抗肿瘤功效。H＆E和Ki67染色测试显示，肿瘤区域明显坏死，细胞增殖弱。因此，FPCH-DOX NPs是用于高效癌症治疗学的有前途的多功能纳米平台。